Advertisement
U.S. markets closed

Pharma-Bio Serv, Inc. (PBSV)

Other OTC - Other OTC Delayed Price. Currency in USD
0.84700.0000 (0.00%)
At close: 01:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8470
Open0.7900
BidN/A x N/A
AskN/A x N/A
Day's Range0.8470 - 0.8470
52 Week Range0.7200 - 1.1000
Volume1,950
Avg. Volume3,822
Market Cap19.448M
Beta (5Y Monthly)0.52
PE Ratio (TTM)28.23
EPS (TTM)0.0300
Earnings DateJun 12, 2024 - Jun 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 29, 2024
1y Target Est1.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for PBSV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PHARMA-BIO SERVICES INC
    Analyst Report: Ecolab, Inc.Ecolab is a provider of water, hygiene, and energy technology and services. The company delivers comprehensive solutions to promote safe food, maintain clean environments, optimize water and energy use, and improve operational efficiency for customers in the food, healthcare, energy, hospitality, and industrial sectors. Ecolab has over 48,000 employees worldwide. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Zacks Small Cap Research

    PBSV Releases Quarterly Results

    By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced results for the quarter ended January 31, 2024. The headline was below expectations and management noted that the company was “challenged” in the quarter. Management didn’t elaborate on what those challenges were, but all geographical segments of the company’s business suffered losses and saw

  • ACCESSWIRE

    Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024

    DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, ...

  • Zacks Small Cap Research

    PBSV Expands Margins and Markets

    By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced its full year 2023 (October) results. The headline showed that earnings per share of $0.06 were slightly below our estimates as revenues dropped modestly from the previous year. However, the company continues to report continued impressive improvement in gross margin on sales revenue by 4.6%